学术论文 | 研究方向 | 科研项目 | 招生计划
Yao, L. Sun, J. Hu, L. Chen, J. Zhang, J. Xu, Y. Xie, Y#. Ovarian cancer risk of Chinese women with BRCA1/2 germline pathogenic variants,Journal of human genetics,67(11):639-42
Tan, Y. Yao, L. Gamliel, A. Nair, S. J. Taylor, H. Ohgi, K. Aggarwal, A. K. Rosenfeld, M. G*. Signal-induced enhancer activation requires Ku70 to read topoisomerase1-DNA covalent complexes,Nat Struct Mol Biol,30(2):148-58
Zang, F#. Ding, X#. Chen, J. Hu, L. Sun, J. Zhang, J. Xu, Y. Yao, L*. Xie, Y*. Prevalence of BRCA1 and BRCA2 pathogenic variants in 8627 unselected patients with breast cancer: stratification of age at diagnosis, family history and molecular subtype,Breast Cancer Res Treat,195(3):431-9
Liu X#, Wang Y#, Cao K#, Yao L#, Hu L, Sun J, Zhang J, Xu Y, Xie Y*. Impact of multifocal or multicentric disease on local recurrence and survival in breast cancer patients with or without BRCA1/2 variants,Breast Cancer Res Treat,199(1):25-33
Zhang, J#. Yao, L#. Liu, Y. Ouyang, T. Li, J. Wang, T. Fan, Z. Fan, T. Lin, B. Xie, Y*. Impact of the addition of carboplatin to anthracycline-taxane-based neoadjuvant chemotherapy on survival in BRCA1/2-mutated triple-negative breast cancer,Int J Cancer,2021.148: 941-9
Meng, H#. Yao, L#. Yuan, H#. Xu, Y. Ouyang, T. Li, J. Wang, T. Fan, Z. Fan, T. Lin, B. Xie, Y*. BRCA1 c.5470_5477del, a founder mutation in Chinese Han breast cancer patients,Int J Cancer,2020. 146: 3044-52
Fu, F#. Zhang, D#. Hu, L#. Sundaram, S. Ying, D. Zhang, Y. Fu, S. Zhang, J. Yao, L. Xu, Y. Xie, Y*. Association between 15 known or potential breast cancer susceptibility genes and breast cancer risks in Chinese women,Cancer Biol Med,
Sheng, S. Xu, Y. Guo, Y. Yao, L. Hu, L. Ouyang, T. Li, J. Wang, T. Fan, Z. Fan, T. Lin, B. Xie, Y.* Prevalence and clinical impact of TP53 germline mutations in Chinese women with breast cancer,Int J Cancer,2020.146(2):487-495
BARD1胚系突变在乳腺癌DNA损伤应答中的作用及潜在临床意义, 课题负责人, 2023.1.1~2026.12.31, 国家自然科学基金面上项目
中国人群特异BRCA1/2重复突变的乳腺癌发病风险评估及功能研究, 课题负责人, 2017.1.1~2020.12.31, 国家自然科学基金面上项目
DNA修复基因致病性突变对乳腺癌新辅助化疗疗效的预测作用, 课题负责人, 2021.1.1~2023.12.31, 北京市医管局培育项目
中国家族性乳腺癌BRCA1/2基因大片段重排断裂位点鉴定及功能研究, 参加者, 2018.1.1~2021.12.31, 国家自然科学基金面上项目
社会任职
- 中国抗癌协会家族遗传性肿瘤专业委员会委员
- 中国抗癌协会乳腺癌专业委员会会员
- 中国抗癌协会肿瘤流行病学专业委员会会员
- 中国抗癌协会肿瘤分子医院专业委员会会员
学习、工作经历
- 2009.8.1~,北京大学肿瘤医院 家族遗传性肿瘤中心实验室 历任助理研究员 副研究员 副教授
- 2004.9.1~2009.7.31,北京大学医学部 分子病理学 医学博士
- 1999.9.1~2004.7.31,北京大学医学部 医学学士